Pramipexol
Pramipexol
Klass : A
Visa all info
Skriv ut
Kontakta oss
Produkter
Visa alla produkter
Derinik, MIRAPEXIN, Mirapexin, Oprymea, Pramipexol 2care4, Pramipexol ......
Derinik, MIRAPEXIN, Mirapexin, Oprymea, Pramipexol 2care4, Pramipexol Aurobindo, Pramipexol Ebb, Pramipexol STADA, Pramipexol Sandoz, Pramipexol Teva Pharma, Pramipexol Zentiva, Pramipexole Accord, Pramipexole Bluefish, Pramipexole Orion, Pramipexole Sandoz, Pramipexole Teva, SIFROL, SifrolATC-koder
N04BC05
N04BC05Substanser
pramipexol, pramipexoldihydrokloridmonohydrat
pramipexol, pramipexoldihydrokloridmonohydratSammanfattning
Kliniska prövningar utförda av läkemedelsföretaget har inte påvisat könsskillnader i effekt eller biverkningar hos patienter som behandlas med pramipexol för Parkinsons sjukdom. Hos patienter som behandlas med pramipexol mot rastlösa ben RLS (Restless Legs Syndrome) rapporterades illamående och trötthet oftare av kvinnor än män.
Kliniska prövningar utförda av läkemedelsföretaget har inte påvisat könsskillnader i effekt eller biverkningar hos patienter som behandlas med pramipexol för Parkinsons sjukdom. Hos patienter som behandlas med pramipexol mot rastlösa ben RLS (Restless Legs Syndrome) rapporterades illamående och trötthet oftare av kvinnor än män.Background
The reported incidence and prevalence of Parkinson’s disease (PD) is slightly higher in men than in women. It seems that men develop PD earlier in life compared to women. Several possible explanations behind these sex differences have been suggested; the protective role of estrogens in premenopausal women, and different profiles of risk factors (environmental and/or genetic). Sex differences in clinical presentations of PD have also been reported. Since the activities of daily living might differ between men and women with PD, different treatment strategies can be recommended to men and women with PD [1]. Visa hela bakgrundstexten
Pharmacokinetics and dosing
In a pharmacokinetic study in healthy volunteers (8 men, 8 women), AUC and Cmax of pramipexol were significantly higher in women for the dose 1.5 mg. The mean creatinine clearance was lower in women than in men (80.9 ±15.6 vs. 112 ±12.8 mL/min/1.73 m2). However, women had higher mean age in this study, and aging leads to a decline in glomerular filtration rate. Also, the normal range of glomerular filtration rate, measured by inulin clearance, is lower......
Försäljning på recept
Visa hela försäljning på recept
Fler kvinnor än män hämtade ut tabletter innehållande pramipexol (ATC-kod N04BC05) på recept i Sverige år 2019, totalt 23 517 kvinnor och 15 143 män. Det motsvarar 4,6 respektive 2,9 personer per tusen invånare. Andelen som hämtat ut läkemedel ökade med stigande ålder hos båda könen. I genomsnitt var tabletter innehållande pramipexol 1,5 gånger vanligare hos kvinnor [9].
Referenser
Visa referenser
Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz GM. Gender differences in Parkinson's disease: A clinical perspective. Acta Neurol Scand. 2017;136(6):570-584.
Wright CE, Sisson TL, Ichhpurani AK, Peters GR. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol. 1997;37:520-5.
Mirapex (pramipexole dihydrochloride). DailyMed [www]. US National Library of Medicine. [updated 2018-05-01, cited 2019-11-07].
Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]
Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, Moberg PJ, Stern MB. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969-73.
Schreglmann SR, Gantenbein AR, Eisele G, Baumann CR. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord. 2012;18:207-9.
Carrière N, Kreisler A, Dujardin K, Destée A, Defebvre L. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients]. Rev Neurol (Paris). 2012;168:143-51.
Poletti M, Logi C, Lucetti C, Del Dotto P, Baldacci F, Vergallo A, Ulivi M, Del Sarto S, Rossi G, Ceravolo R, Bonuccelli U. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol. 2013;33(5):691-4.
Garcia-Ruiz, P J Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, Mata M, Olmedilla Gonzalez N, Mahillo Fernandez I. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840-4.
- Georgiev D, Hamberg K, Hariz M, Forsgren L, Hariz GM. Gender differences in Parkinson's disease: A clinical perspective. Acta Neurol Scand. 2017;136(6):570-584.
- Wright CE, Sisson TL, Ichhpurani AK, Peters GR. Steady-state pharmacokinetic properties of pramipexole in healthy volunteers. J Clin Pharmacol. 1997;37:520-5.
- Mirapex (pramipexole dihydrochloride). DailyMed [www]. US National Library of Medicine. [updated 2018-05-01, cited 2019-11-07].
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2019 [cited 2020-03-10.]
- Weintraub D, Siderowf AD, Potenza MN, Goveas J, Morales KH, Duda JE, Moberg PJ, Stern MB. Association of dopamine agonist use with impulse control disorders in Parkinson disease. Arch Neurol. 2006;63(7):969-73.
- Schreglmann SR, Gantenbein AR, Eisele G, Baumann CR. Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism Relat Disord. 2012;18:207-9.
- Carrière N, Kreisler A, Dujardin K, Destée A, Defebvre L. [Impulse control disorders in Parkinson's disease: A cohort of 35 patients]. Rev Neurol (Paris). 2012;168:143-51.
- Poletti M, Logi C, Lucetti C, Del Dotto P, Baldacci F, Vergallo A, Ulivi M, Del Sarto S, Rossi G, Ceravolo R, Bonuccelli U. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol. 2013;33(5):691-4.
- Garcia-Ruiz, P J Martinez Castrillo JC, Alonso-Canovas A, Herranz Barcenas A, Vela L, Sanchez Alonso P, Mata M, Olmedilla Gonzalez N, Mahillo Fernandez I. Impulse control disorder in patients with Parkinson's disease under dopamine agonist therapy: a multicentre study. J Neurol Neurosurg Psychiatry. 2014;85(8):840-4.
Uppdaterat
Litteratursökningsdatum: 11/7/2019
Litteratursökningsdatum: 11/7/2019Se även
Ropinirol
Rotigotin